ALK and non-small cell lung carcinoma: First‐line treatment of patients with stage III NSCLC who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC. Patients' tumors must have no EGFR or ALK genomic aberrations and express PD‐L1 (Tumor Proportion Score [TPS] ≥ 1%) determined by an FDA‐approved test [13]